Oragenics (NYSEAMERICAN:OGEN) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Oragenics (NYSEAMERICAN:OGEN) in a report issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Oragenics Price Performance

Shares of OGEN opened at $3.61 on Monday. The stock’s 50-day simple moving average is $3.41 and its 200 day simple moving average is $3.71. Oragenics has a 52-week low of $2.60 and a 52-week high of $12.75.

Hedge Funds Weigh In On Oragenics

Several institutional investors have recently modified their holdings of OGEN. Renaissance Technologies LLC increased its position in shares of Oragenics by 24.4% during the 4th quarter. Renaissance Technologies LLC now owns 288,398 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 56,498 shares during the last quarter. Millennium Management LLC increased its position in shares of Oragenics by 591.6% during the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 110,119 shares during the last quarter. Finally, State Street Corp increased its position in shares of Oragenics by 8.1% during the 1st quarter. State Street Corp now owns 495,563 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 37,338 shares during the last quarter. 2.07% of the stock is currently owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.